Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Lieber, André  [Clear All Filters]
Journal Article
Wang H, Georgakopoulou A, Zhang W, Kim J, Gil S, Ehrhardt A, Lieber A. HDAd6/35++ - A new helper-dependent adenovirus vector platform for transduction of hematopoietic stem cells. Mol Ther Methods Clin Dev. 2023;29:213-226.
Wang H, Liu Z, Li C, Gil S, Papayannopoulou T, Doering CB, Lieber A. High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells. Blood Adv. 2019;3(19):2883-2894.
Wang H, Georgakopoulou A, Psatha N, Li C, Capsali C, Samal HBhusan, Anagnostopoulos A, Ehrhardt A, Izsvák Z, Papayannopoulou T, et al. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia. J Clin Invest. 2018.
Li C, Wang H, Georgakopoulou A, Gil S, Yannaki E, Lieber A. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model. Mol Ther. 2020.
Li C, Georgakopoulou A, Newby GA, Chen PJ, Everette KA, Paschoudi K, Vlachaki E, Gil S, Anderson AK, Koob T, et al. In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model. Blood. 2023.
Saydaminova K, Strauss R, Xie M, Bartek J, Richter M, van Rensburg R, Drescher C, Ehrhardt A, Ding S, Lieber A. Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells. Cancer Biol Ther. 2016.
Li C, Goncalves KA, Raskó T, Pande A, Gil S, Liu Z, Izsvák Z, Papayannopoulou T, Davis JC, Kiem H-P, et al. Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice. Blood Adv. 2021;5(5):1239-1249.
Choi I-K, Strauss R, Richter M, Yun C-O, Lieber A. Strategies to increase drug penetration in solid tumors. Front Oncol. 2013;3:193.